Recombinant Bovine Growth Hormone vs Sucralose: which is worse?

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

What is Sucralose?

Sucralose is a synthetic non-caloric sweetener made by selectively chlorinating three hydroxyl groups in sucrose (table sugar). Despite being derived from sugar, the chlorination makes it non-digestible: most passes through the body without being metabolized. It is approximately 600 times sweeter than sucrose.

Documented risks

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.

Sucralose: A 2023 study published in Nature Medicine found that sucralose-1,6-hexanediacid — a gut-derived metabolite of sucralose — enhanced T-cell immune activity in vitro. The researchers found that sucralose exposure in certain doses could potentially affect immune function. However, this was an early-stage study and its clinical implications for humans are not established. A 2021 Cell study found that sucralose and other non-nutritive sweeteners altered gut microbiome composition and glucose tolerance in human participants who were non-habitual sweetener users. The study found sucralose consumption was associated with glucose intolerance changes in some individuals, suggesting gut microbiome-mediated effects on metabolism. A 2016 study in the International Journal of Occupational and Environmental Health found sucralose consumption was associated with higher leukemia incidence in male mice at high lifetime doses. This finding prompted significant concern, though regulators noted the doses used far exceeded typical human intake. Chlorinated compounds: sucralose contains chlorine atoms in its structure. Critics have argued this makes it similar to organochlorine compounds, some of which are known carcinogens. Regulatory agencies have reviewed this and do not consider the chlorine in sucralose equivalent to organochlorine pollutants; the chlorinated positions are not metabolically active. However, high-temperature cooking with sucralose can generate chlorinated compounds. EFSA's 2017 re-evaluation concluded sucralose is safe and non-carcinogenic at its ADI of 15 mg/kg body weight. The FDA ADI of 5 mg/kg/day provides a substantial safety margin relative to typical consumer intake from Splenda use.